Preemptive therapy for hepatitis C virus after living-donor liver transplantation

Transplantation

Volumn 78, Issue 9, 2004, Pages 1308-1311

  Sugawara, Yasuhiko ^a   Makuuchi, Masatoshi ^a   Matsui, Yuichi ^a   Kishi, Yoji ^a   Akamatsu, Nobuhisa ^a   Kaneko, Junichi ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Hepatitis C virus; Interferon; Living donor liver transplantation; Rivabirin

Indexed keywords

ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; ERYTHROPOIETIN; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ANEMIA; ARTICLE; CHILL; CLINICAL ARTICLE; DEPRESSION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GRAFT SURVIVAL; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTOPENIA;

ADULT; ALANINE TRANSAMINASE; FEMALE; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RECURRENCE; RNA, VIRAL;

EID: 8644222054     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000142677.12473.E5     Document Type: Article

References (26)

1. EASL International Consensus Conference on Hepatitis C, Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956.
2. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815.
3. Dickson RC, Caldwell SH, Ishitani MB, et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996; 61: 701.
4. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
5. Troppmann C, Rossaro L, Perez RV, et al. Early, rapidly progressive cholestatic hepatitis C reinfection and graft loss after adult living donor liver transplantation. Am J Transplant 2003; 3: 239.
6. Taniguchi M, Wachs M, Bak T, et al. Hepatitis C recurrence in living donor liver transplantation. Am J Transplant 2002; 2(suppl 3): 138.
7. Ghobrial RM, Amersi F, Farmer DG, et al. Rapid and severe early HCV recurrence following adult living donor liver transplantation. Am J Transplant 2002; 2(suppl 3): 163.
8. Russo MW, Galanko J, Beavers K, et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004; 10: 340.
9. Van Vlierberghe H, Troisi R, Colle I, et al. Hepatitis C infection-related liver disease: Patterns of recurrence and outcome in cadaveric and living-donor liver transplantation in adults. Transplantation 2004; 77: 210.
10. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C: International Liver Transplantation Society Expert Panel. Liver Transpl 2003; 9: S1.
11. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 1355.
12. Sugawara Y, Makuuchi M, Sano K, et al. Vein reconstruction in modified right liver graft for living donor liver transplantation. Ann Surg 2003; 237: 180.
13. Sugawara Y, Makuuchi M, Kaneko J, et al. Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant 2002; 16: 102.
14. Sugawara Y, Makuuchi M, Kaneko J, et al. Risk factors for acute rejection in living donor liver transplantation. Clin Transplant 2003; 17: 347.
15. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatohgy 1994; 19: 1321.
16. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77.
17. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696.
18. Urata K, Kawasaki S, Matsunami H, et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatohgy 1995; 21: 1317.
19. Everson GT, Trotter J. Role of adult living donor liver transplantation in patients with hepatitis C. Liver Transpl 2003; 9(10 suppl 2): S64.
20. Trotter JF, Schiano T, Wachs M, et al. Preliminary report: Hepatitis C occurs earlier and is more severe in living donor liver transplant recipients. Am J Transplant 2001; 1: 316A.
21. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatohgy 1998; 28: 831.
22. Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial. Transplantation 1998; 65: 82.
23. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003; 124: 642.
24. Chan SE, Rosen HR. Outcome and management of hepatitis C in liver transplant recipients. Clin Infect Dis 2003; 37: 807.
25. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and efficacy. Liver Transpl 2002; 8: 623.
26. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl 2003; 9: S95.